Likewise, among ovarian cancer patients free from selection biases, the rate of detection of variants in BRCA1/BRCA2 was roughly 20%, whereas the rate for MGP analysis ranged from 26% to 31%, corresponding to a 1.5-fold elevation [30,31]. This evidence concerns the gene BRCA2 and ovarian carcinoma.